share_log

BRIEF-TG Therapeutics Completes Rolling Submission Of Biologics License Application To The U.S. Food And Drug Administration

BRIEF-TG Therapeutics Completes Rolling Submission Of Biologics License Application To The U.S. Food And Drug Administration

Brief-TG治療公司完成向美國食品和藥物管理局滾動提交生物製品許可證申請
路透社 ·  2021/03/29 20:13

March 29 (Reuters) - TG Therapeutics Inc :
   * TG THERAPEUTICS COMPLETES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR UBLITUXIMAB IN COMBINATION WITH UKONIQ™(UMBRALISIB) AS A TREATMENT FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
   * TG THERAPEUTICS COMPLETES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR UBLITUXIMAB IN COMBINATION WITH UKONIQ™(UMBRALISIB) AS A TREATMENT FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)

路透3月29日電-TG治療公司：*TG治療公司完成向美國食品和藥物管理局滾動提交生物製品許可證申請，將UBLITUXIMAB與UKONIQ™(UMBRALISIB)聯合用於治療慢性淋巴細胞白血病患者*TG治療公司完成向美國食品和藥物管理局滾動提交生物製品許可證申請，將UBLITUXIMAB與UKONIQ™(UMBRALISIB)聯合用於治療慢性淋巴細胞白血病患者Eikon的源文本：進一步的公司報道：(Reurs.Briefs@thomsonreurs.com；)

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論